Studies have shown that pembrolizumab and durvalumab can inhibit PD-1/PD-L1 in human non-small cell lung cancer, subsequently activating NK cells and exerting effective anti-tumor immune responses (149, 150). This evidence concerns the gene CD274 and neoplasm.